Skip to main content

Advertisement

Table 2 Drug interactions at 50% killing between cisplatin and the chemicals that inhibit the FA pathway in FA pathway-deficient/proficient ovarian cancer cells

From: Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin

  Interaction with cisplatin
2008 2008 + FANCF
Chemicals FA-deficient FA-proficient
CI Interpretation CI Interpretation
Bortezomib 1.00 ± 0.05 Additive 0.88 ± 0.02 Moderate synergism
Lactacystin 0.90 ± 0.05 Slight synergism 1.02 ± 0.05 Additive
MG132 1.13 ± 0.04 Slight antagonism 1.13 ± 0.05 Slight antagonism
ALLN 1.17 ± 0.04 Slight antagonism 1.06 ± 0.09 Additive
5929407 1.10 ± 0.04 Additive 1.00 ± 0.04 Additive
Curcumin 0.98 ± 0.02 Additive 1.06 ± 0.02 Additive
H-9 1.08 ± 0.04 Additive 0.98 ± 0.04 Additive
Gö6976 0.63 ± 0.04 Synergism 0.68 ± 0.03 Synergism
SB218078 0.90 ± 0.05 Slight synergism 0.77 ± 0.03 Moderate synergism
UCN-01 0.83 ± 0.03 Moderate synergism 0.66 ± 0.04 Synergism
Alsterpaullone 1.05 ± 0.03 Additive 1.15 ± 0.03 Slight antagonism
Roscovitine 0.98 ± 0.03 Additive 0.98 ± 0.03 Additive
Geldanamycin 0.83 ± 0.04 Moderate synergism 0.38 ± 0.05 Synergism
17-AAG 1.06 ± 0.10 Additive 0.87 ± 0.04 Slight synergism
CA-074-Me 0.91 ± 0.03 Additive 0.78 ± 0.02 Moderate synergism
Chloroquine 0.88 ± 0.05 Slight synergism 0.72 ± 0.05 Moderate synergism
Wortmannin 1.08 ± 0.05 Additive 1.12 ± 0.05 Slight antagonism
DRB 1.08 ± 0.04 Additive 0.97 ± 0.05 Additive
HNMPA-(AM)3 0.96 ± 0.02 Additive 0.91 ± 0.03 Additive
Puromycin 1.08 ± 0.03 Additive 0.88 ± 0.04 Slight synergism
TPEN 1.16 ± 0.08 Slight antagonism 1.13 ± 0.04 Slight antagonism
5656325 0.99 ± 0.03 Additive 1.05 ± 0.05 Slight antagonism
5315179 1.14 ± 0.09 Slight antagonism 0.94 ± 0.04 Additive
7012246 1.18 ± 0.05 Slight antagonism 0.87 ± 0.04 Slight synergism
5195243 1.22 ± 0.04 Moderate antagonism 1.02 ± 0.02 Additive
5373662 1.08 ± 0.04 Additive 0.90 ± 0.04 Slight synergism
  1. Combination index (CI) at 50% killing values (mean ± SEM) calculated from isobologram at the LD50 level analyses of combination of cisplatin with each FA pathway inhibitor, performed in FA-deficient (2008) and FA-proficient (2008 + FANCF) ovarian cancer cell lines. See Figure 4 and Additional file 9: Figure S7 for details. Interpretation of combination index values: 0.10 < CI ≤ 0.30, strong synergism; 0.30 < CI ≤ 0.70, synergism; 0.70 < CI ≤ 0.85, moderate synergism; 0.85 < CI ≤ 0.90, slight synergism; 0.90 < CI ≤ 1.10, additivity; 1.10 < CI ≤ 1.20, slight antagonism; 1.20 < CI ≤ 1.45, moderate antagonism [26]. Synergism is highlighted in bold letters.